Nanoparticle Influenza Peptide Vaccine for Broad T- and B-Cell Immunity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional influenza vaccines are not completely protective due to antigenic variations and lack induction of T cell responses, necessitating frequent updates and being costly, while existing universal vaccine formulations often cause adverse reactions.
Innovation Solution
A vaccine composition comprising immunogenic influenza virus peptides attached to nanoparticles, specifically CD8+ T cell and B cell epitopes, to stimulate both humoral and cellular immune responses, eliminating the need for adjuvants and providing broad protection against seasonal and pandemic strains.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional influenza vaccines are used, then humoral immunity is induced, but protection is incomplete due to antigenic variations and lack of T cell response
Solution Approach 1:
The vaccine divides the influenza virus into discrete peptide segments representing conserved epitopes from multiple viral proteins (hemagglutinin, neuraminidase, matrix, nucleoprotein). These segmented peptides are presented on nanoparticles to induce both humoral and cellular immune responses against specific viral regions that remain conserved across strains.
Solution Approach 2:
The vaccine uses a universal nanoparticle platform displaying multiple conserved peptide epitopes that can elicit cross-subtype immune responses. The same nanoparticle structure presents different peptide combinations to target multiple influenza subtypes simultaneously, providing broad protective coverage.
2Reliability
If conventional influenza vaccines are updated yearly, then protection matches current strains, but production cost increases and protection against novel mid-season strains is unavailable
Solution Approach 1:
The vaccine pre-targets conserved epitopes that are predicted to remain protective across future influenza strains. By focusing on evolutionarily conserved regions rather than current dominant strains, the vaccine maintains effectiveness against novel strains emerging in future seasons without requiring reformulation.
Solution Approach 2:
The vaccine changes the target parameter from variable surface glycoproteins (HA, NA) to conserved internal peptide epitopes. This parameter shift from extracellular to intracellular targets fundamentally alters the vaccine's ability to maintain effectiveness despite viral evolution.
3Reliability
If conventional influenza vaccines are designed for antibody-based protection, then humoral immunity is induced, but T cell responses that eliminate infected cells are not adequately stimulated
Solution Approach 1:
The vaccine merges B cell epitopes (for humoral immunity) and T cell epitopes (for cellular immunity) onto a single nanoparticle platform. This combination allows simultaneous induction of both antibody production and T cell activation against influenza virus, addressing the limitation of conventional vaccines that target only one arm of the immune system.
Data Source
AI summary
The invention provides a vaccine composition comprising an influenza virus peptide comprising a CD8+ T cell epitope and an influenza virus peptide comprising a B cell epitope, wherein each peptide is attached to a nanoparticle.